gdc
CLL Monthly Minutes

CLL Monthly Minutes

CLL Monthly MinutesLeukemia
The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL.
CLL Monthly MinutesLeukemia
During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL.
CLL Monthly MinutesLeukemia
Identifying the risk factors for infection may allow preventive measures to be taken to protect patients.
CLL Monthly MinutesLeukemia
Oral targeted therapies have revolutionized treatment for patients with CLL but ensuring that they are taken as prescribed is crucial to achieving optimal outcomes.
CLL Monthly MinutesLeukemia
Copay assistance coupons and copay adjustment programs put patients in the middle of healthcare cost-saving measures.
CLL Monthly MinutesLeukemia
Currently, many effective, well-tolerated treatments exist, with high expectations for new drugs and regimens to be developed and approved in the near future.
CLL Monthly MinutesLeukemia
A literature review found a set of physical, psychological, social, and spiritual topics that could be used to better educate patients throughout their CLL treatment journey.
CLL Monthly MinutesLeukemia
COVID-19 vaccination is generally safe for immunocompromised patients, including those with CLL, although the efficacy is substantially lower than in healthy individuals.
CLL Monthly MinutesLeukemia
Cell-based assays and animal data suggest that ZN-d5 may be a tolerable and effective treatment for patients with leukemias and lymphomas.
CLL Monthly MinutesLeukemia
The first head-to-head trial of these drugs shows comparable efficacy with a better cardiovascular safety profile for acalabrutinib.
Page 1 of 5
Results 1 - 10 of 42

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest